“Federal Government Invests Over 400 Million Pesos in Development of Homeland Vaccine for COVID-19”

For the development of the homeland vaccine against COVID-19, which has yet to be approved, the federal government would have spent more than 400 million pesos.

According to the request for information 330010923000132 of the National Transparency Platform, the National Council of Science and Technology (Conacyt) reported that in 2020 135 million 264 thousand 464 pesos were allocated for the development of the vaccine.

A year later, in 2021, another 49 million 224 thousand 23 pesos were invested under the same concept and for 2022, destined for the second part of intermediate results in processed samples, 40 million 127 thousand 833 pesos were allocated.

Finally, during the same year, for conducting the study of phases II and III of the project, 198 million 281 thousand 619 pesos were allocated. In total, the government allocated around 422 million pesos.

“We already have the Patria vaccine,” announces the @Conacyt_MX@ElenaBuylla reported that the Patria vaccine, made in Mexico to deal with COVID-19, is already authorized and that it can be used as a booster dose in vaccination schemes. pic.twitter.com/ZNexEMT2RH

— Politician MX (@politicomx) May 3, 2023

To this we must add that on April 13, 2021, the director of Conacyt, María Elena Álvarez-Buylla Roces, mentioned the contribution of 15 million more by the Mexican Agency for International Development Cooperation (Amexcid). Which amounts to 437 million pesos.

On May 3rd, Maria Elena Alvarez-Buyllaannounced that the Mexican vaccine was already in its final phase, which will be used as a booster dose against the virus.

declared during a morning press conference that the data from the final phase are successful and meet the criteria established by the World Health Organization (OMS). There he himself stressed that it was developed in record time.

However, Andrés Manuel López Obrador had initially stated December 2021 as the tentative end date.

Alvarez-Buylla He pointed out that the vaccine is ready but the approval of the Federal Commission for the Protection against Sanitary Risks is lacking (cofepris) to start mass production, which is expected to be between September and December of this year.